Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 193
interventional 183
Observational 9
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 98
Drug|Other 18
Biological 13
Drug|Procedure 7
Biological|Drug 6
Biological|Other 5
Drug|Other|Procedure|Radiation 5
Drug|Genetic|Other 4
Biological|Drug|Other 3
Biological|Drug|Other|Procedure 3
Biological|Drug|Procedure|Radiation 3
Dietary Supplement|Drug 3
Biological|Drug|Other|Procedure|Radiation 2
Dietary Supplement|Other 2
Drug|Procedure|Radiation 2
Drug|Radiation 2
Biological|Other|Procedure 1
Biological|Procedure|Radiation 1
Biological|Radiation 1
Device|Other 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|Procedure 1
Genetic 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 93
China 21
Japan 9
United States|Canada 7
Korea, Republic of 6
Italy 4
United Kingdom 4
United States|Italy 4
United States|Germany|Italy 3
Belgium|France 2
Canada 2
France 2
NA 2
Austria|Belgium|Czechia|Denmark|Finland|Germany|Netherlands|Norway|Poland|Portugal|Sweden 1
Belgium|France|Germany|Italy|Korea, Republic of|Portugal|Singapore|Spain 1
Denmark|Finland|Norway 1
Denmark|France|Italy|Netherlands|Spain|United Kingdom 1
Hong Kong 1
Hong Kong|Japan|Korea, Republic of|Taiwan 1
Japan|Korea, Republic of 1
Korea, Republic of|Malaysia|Singapore 1
Singapore 1
Taiwan 1
Thailand 1
United States|Australia 1
United States|Australia|Austria|Belarus|Belgium|Brazil|Bulgaria|Canada|Chile|Czechia|Denmark|Egypt|France|Germany|Hungary|Israel|Italy|Mexico|Netherlands|New Zealand|Peru|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Slovakia|Spain|Sweden|Turkey|United Kingdom 1
United States|Australia|Canada 1
United States|Australia|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Poland|Romania|Spain|Taiwan|United Kingdom 1
United States|Australia|Czechia|France|Germany|Poland|Spain|Sweden|Ukraine|United Kingdom 1
United States|Australia|France|Italy|Korea, Republic of|Poland|Russian Federation|Spain|Turkey 1
United States|Belgium|Canada|Croatia|Denmark|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Slovakia|South Africa|Spain|United Kingdom 1
United States|Belgium|Canada|France|Italy|United Kingdom 1
United States|Canada|China|France|Germany|Hong Kong|Italy|Taiwan 1
United States|France|Germany|Italy|Spain|United Kingdom 1
United States|France|Italy|Netherlands|Spain|Switzerland 1
United States|Korea, Republic of|Spain 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 79
2 14
3 10
4 8
5 14
6 3
7 3
8 5
9 2
10 2
11 4
12 3
13 5
15 2
16 1
17 2
20 3
21 4
23 2
24 1
31 1
32 2
34 1
36 1
39 1
40 1
47 1
49 1
59 1
90 1
117 1
131 1
144 1
152 1
161 1

Phase

Phase Study_Count
Phase 2 76
Phase 1 51
Phase 1/Phase 2 33
N/A 8
Phase 3 7
Phase 4 5
Early Phase 1 3

Number of Arms

Number_of_Arms Count_of_Studies
1 130
2 30
3 8
4 4
5 1
6 2
7 1
8 1
NA 6

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 6.00000 5.000 2.00000 18.0000 1.00000 85.0000 22.0
1st Qu. 19.50000 26.750 17.00000 37.0000 35.75000 115.5000 50.0
Median 33.00000 51.000 27.00000 50.0000 60.00000 244.0000 100.0
Mean 26.33333 150.375 38.56863 57.0303 69.56579 243.4286 74.4
3rd Qu. 36.50000 163.500 49.00000 62.0000 93.25000 346.0000 100.0
Max. 40.00000 713.000 133.00000 149.0000 250.00000 452.0000 100.0

Trial Group Type

group_type Group_Count
Experimental 245
Active Comparator 11
NA 6
No Intervention 3
Other 3

Intervention Model

intervention_model Study_Count
Single Group Assignment 146
Parallel Assignment 28
Sequential Assignment 9

Primary Purpose

primary_purpose Study_Count
Treatment 177
Prevention 2
Supportive Care 2
Basic Science 1
Diagnostic 1

Observational Studies

Studies by Country

Country Study_Count
United States 3
Japan 2
Korea, Republic of 2
Spain 1
United States|Argentina|Brazil|Chile|China|France|Israel|Italy|Korea, Republic of|Slovakia|Spain|Switzerland|United Kingdom|Uruguay 1

Sites per Study

Site_count Study_Count
1 4
2 1
3 1
10 1
68 1
76 1

Enrollment Metrics

Measure Observational
Min 33.0000
1st Qu 86.0000
Median 198.0000
Mean 704.8889
3rd Qu 800.0000
Max 3000.0000

Observation Model

observational_model Study_Count
Cohort 6
Case-Only 2
NA 1

Time Perspective

time_perspective Study_Count
Prospective 5
Retrospective 4

Registries

Studies by Country

Country Study_Count
United States|Italy|Romania|Ukraine 1

Sites per Study

Site_count Study_Count
6 1

Enrollment Metrics

Measure Registries
Min 1000
1st Qu 1000
Median 1000
Mean 1000
3rd Qu 1000
Max 1000

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
2 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03947255 A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03947255 Recruiting Seattle Genetics, Inc. 2024-12-31
NCT03552692 Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03552692 Active, not recruiting Fondazione Italiana Linfomi ONLUS 2020-08-31
NCT03372057 A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT03372057 Recruiting Verastem, Inc. 2021-11-30
NCT03321890 Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT03321890 Recruiting Sun Yat-sen University 2020-12-01
NCT03278782 Study of Pembrolizumab (MK-3475) in Combination With Romidepsin https://ClinicalTrials.gov/show/NCT03278782 Active, not recruiting M.D. Anderson Cancer Center 2020-11-30
NCT03268889 Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) https://ClinicalTrials.gov/show/NCT03268889 Recruiting The First Affiliated Hospital of Soochow University 2020-06-15
NCT03212937 Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03212937 Active, not recruiting National Cancer Centre, Singapore 2020-02-29
NCT03210662 Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03210662 Recruiting M.D. Anderson Cancer Center 2020-11-30
NCT03150602 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy https://ClinicalTrials.gov/show/NCT03150602 Recruiting Taiwan Mundipharma Pharmaceuticals Ltd. 2020-12-31
NCT03141203 Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT03141203 Active, not recruiting University of Birmingham 2020-08-31
NCT03113500 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03113500 Recruiting City of Hope Medical Center 2021-01-21
NCT03071822 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas https://ClinicalTrials.gov/show/NCT03071822 Recruiting The University of Hong Kong 2021-07-31
NCT03046953 Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03046953 Recruiting University of Birmingham 2020-08-31
NCT03017820 VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03017820 Recruiting Mayo Clinic 2021-01-15
NCT03011814 Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03011814 Recruiting City of Hope Medical Center 2023-03-08
NCT02987244 Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02987244 Recruiting Peking Union Medical College Hospital 2020-03-31
NCT02978625 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers https://ClinicalTrials.gov/show/NCT02978625 Recruiting National Cancer Institute (NCI) 2021-06-01
NCT02953652 Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT02953652 Active, not recruiting HUYA Bioscience International 2019-04-30
NCT02879526 Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT02879526 Recruiting The First Affiliated Hospital with Nanjing Medical University 2019-06-30
NCT02809573 Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT02809573 Completed Chipscreen Biosciences, Ltd. 2019-01-08
NCT02797470 Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02797470 Recruiting AIDS Malignancy Consortium 2021-09-30
NCT02689453 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) https://ClinicalTrials.gov/show/NCT02689453 Recruiting National Institutes of Health Clinical Center (CC) 2023-01-31
NCT02676778 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02676778 Completed Eisai Inc. 2019-04-24
NCT02653976 A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT02653976 Active, not recruiting Solasia Pharma K.K. 2019-12-31
NCT02652715 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02652715 Completed Mayo Clinic 2018-12-21
NCT02594267 A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT02594267 Active, not recruiting Acrotech Biopharma LLC 2020-08-31
NCT02588651 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) https://ClinicalTrials.gov/show/NCT02588651 Recruiting Case Comprehensive Cancer Center 2020-08-31
NCT02576496 Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02576496 Recruiting Mundipharma-EDO GmbH 2021-03-31
NCT01716806 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01716806 Recruiting Seattle Genetics, Inc. 2021-09-30
NCT01614197 A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma https://ClinicalTrials.gov/show/NCT01614197 Completed Therapeutic Advances in Childhood Leukemia Consortium 2019-12-15
NCT02567656 Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02567656 Completed Rhizen Pharmaceuticals SA 2018-03-31
NCT02561273 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02561273 Active, not recruiting University of Nebraska 2020-10-31
NCT02535247 Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02535247 Recruiting Fox Chase Cancer Center 2020-12-31
NCT02533700 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL https://ClinicalTrials.gov/show/NCT02533700 Active, not recruiting Shandong Provincial Hospital 2019-05-31
NCT02520791 Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02520791 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT02512497 Romidepsin Maintenance After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02512497 Recruiting Ohio State University Comprehensive Cancer Center 2020-12-31
NCT02495415 Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02495415 Recruiting CerRx, Inc. 2021-07-31
NCT02464228 Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. https://ClinicalTrials.gov/show/NCT02464228 Active, not recruiting Kura Oncology, Inc. 2021-01-15
NCT02445404 Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL https://ClinicalTrials.gov/show/NCT02445404 Recruiting Samsung Medical Center 2020-06-30
NCT02432235 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02432235 Completed ADC Therapeutics S.A. 2019-10-24
NCT02424045 Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02424045 Completed Samsung Medical Center 2017-09-30
NCT02362997 Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL https://ClinicalTrials.gov/show/NCT02362997 Recruiting Dana-Farber Cancer Institute 2020-09-30
NCT02342782 Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02342782 Active, not recruiting City of Hope Medical Center 2020-12-31
NCT02264613 ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT02264613 Active, not recruiting Aileron Therapeutics 2020-03-31
NCT02232516 Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02232516 Recruiting Northwestern University 2022-07-31
NCT02223208 Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02223208 Recruiting Fondazione Italiana Linfomi ONLUS 2021-09-30
NCT02181218 Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas https://ClinicalTrials.gov/show/NCT02181218 Active, not recruiting Washington University School of Medicine 2019-03-28
NCT02168140 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02168140 Active, not recruiting Wake Forest University Health Sciences 2019-04-18
NCT02158975 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02158975 Completed University of Michigan Rogel Cancer Center 2016-10-31
NCT02142530 Carfilzomib Plus Belinostat in Relapsed/Refractory NHL https://ClinicalTrials.gov/show/NCT02142530 Completed Massachusetts General Hospital 2017-03-31
NCT02106650 Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT02106650 Completed Acrotech Biopharma LLC 2018-10-31
NCT01280526 A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01280526 Completed The Lymphoma Academic Research Organisation 2012-11-30
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT04018248 BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) https://ClinicalTrials.gov/show/NCT04018248 Recruiting Boryung Pharmaceutical Co., Ltd 2023-12-31
NCT02013362 Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02013362 Completed Mundipharma K.K. 2015-12-31
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01897012 Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01897012 Completed National Cancer Institute (NCI) 2018-10-31
NCT01846390 Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01846390 Completed Canadian Cancer Trials Group 2016-07-06
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01839097 Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01839097 Completed Acrotech Biopharma LLC 2016-01-31
NCT01822886 Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT01822886 Completed Fondazione Italiana Linfomi ONLUS 2014-12-31
NCT01806337 CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT01806337 Completed University of Göttingen 2006-07-31
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01796002 Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01796002 Active, not recruiting The Lymphoma Academic Research Organisation 2020-03-20
NCT01787409 Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency https://ClinicalTrials.gov/show/NCT01787409 Recruiting Mayo Clinic 2020-11-30
NCT01777152 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas https://ClinicalTrials.gov/show/NCT01777152 Active, not recruiting Seattle Genetics, Inc. 2018-08-15
NCT01776411 Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT01776411 Completed Mundipharma K.K. 2016-03-31
NCT01767766 Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01767766 Completed TG Therapeutics, Inc. 2018-02-28
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01719835 CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study https://ClinicalTrials.gov/show/NCT01719835 Active, not recruiting Royal Marsden NHS Foundation Trust 2016-11-30
NCT01689220 A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea https://ClinicalTrials.gov/show/NCT01689220 Completed Solasia Pharma K.K. 2014-01-31
NCT01679860 Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma https://ClinicalTrials.gov/show/NCT01679860 Completed Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2011-12-31
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01664975 Treatment of Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01664975 Completed Zhengzhou University 2016-04-30
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01644253 Phase 1b Safety and Efficacy Study of TRU-016 https://ClinicalTrials.gov/show/NCT01644253 Active, not recruiting Aptevo Therapeutics 2020-10-31
NCT01638533 Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction https://ClinicalTrials.gov/show/NCT01638533 Active, not recruiting National Cancer Institute (NCI) 2018-11-29
NCT01611142 Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01611142 Completed Kyowa Kirin Pharmaceutical Development, Inc. 2015-05-31
NCT01590732 Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01590732 Completed M.D. Anderson Cancer Center 2018-05-02
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT03349333 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL https://ClinicalTrials.gov/show/NCT03349333 Completed Mundipharma (China) Pharmaceutical Co. Ltd 2017-07-21
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01482962 Alisertib (MLN8237) or Investigator’s Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01482962 Completed Takeda 2015-06-30
NCT01466881 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01466881 Completed National Cancer Institute (NCI) 2014-12-31
NCT01456039 A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01456039 Completed Celgene 2015-07-28
NCT01435863 A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01435863 Completed Solasia Pharma K.K. 2015-04-30
NCT01431209 Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01431209 Active, not recruiting University of Nebraska 2021-03-31
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01403415 Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01403415 Completed National Cancer Institute (NCI) 2015-05-31
NCT01336933 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01336933 Completed University of Nebraska 2016-12-28
NCT01336920 Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01336920 Completed University of Nebraska 2015-04-30
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT04444141 A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04444141 Recruiting Akeso 2021-06-30
NCT04423926 Lenalidomide in Combination With CHOP in Patients With Untreated PTCL https://ClinicalTrials.gov/show/NCT04423926 Recruiting The First Affiliated Hospital with Nanjing Medical University 2022-12-31
NCT04362007 A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04362007 Recruiting Otsuka Pharmaceutical Co., Ltd. 2024-09-30
NCT04329130 Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04329130 Recruiting Sun Yat-sen University 2022-03-26
NCT04254107 A Safety Study of SGN-TGT in Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT04254107 Recruiting Seattle Genetics, Inc. 2022-12-31
NCT04105010 Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) https://ClinicalTrials.gov/show/NCT04105010 Recruiting Dizal (Jiangsu) Pharmaceutical Co., Ltd. 2020-12-31
NCT04101331 Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides https://ClinicalTrials.gov/show/NCT04101331 Recruiting Affimed GmbH 2022-04-30
NCT04083495 CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma https://ClinicalTrials.gov/show/NCT04083495 Recruiting UNC Lineberger Comprehensive Cancer Center 2021-09-30
NCT04061772 A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT04061772 Recruiting Zhejiang Cancer Hospital 2021-07-05
NCT04045470 A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT04045470 Recruiting Dana-Farber Cancer Institute 2023-01-01
NCT04040491 PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04040491 Recruiting Zhengzhou University 2020-12-01
NCT04028440 γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL) https://ClinicalTrials.gov/show/NCT04028440 Recruiting Institute of Hematology & Blood Diseases Hospital 2020-12-31
NCT04008394 Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies https://ClinicalTrials.gov/show/NCT04008394 Recruiting Wuhan Union Hospital, China 2022-07-01
NCT03952572 Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03952572 Recruiting Peking University 2023-04-30
NCT03927105 Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03927105 Active, not recruiting Big Ten Cancer Research Consortium 2024-05-31
NCT03921879 Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT03921879 Recruiting Oncotartis, Inc. 2021-04-30
NCT03905135 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies https://ClinicalTrials.gov/show/NCT03905135 Recruiting National Institutes of Health Clinical Center (CC) 2022-03-01
NCT03902184 IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03902184 Recruiting Innate Pharma 2022-03-01
NCT03776279 A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03776279 Recruiting CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 2020-12-30
NCT03719105 Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma https://ClinicalTrials.gov/show/NCT03719105 Recruiting New York Medical College 2022-12-31
NCT03631862 Treatment of Newly Diagnosed Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03631862 Recruiting Zhengzhou University 2019-12-31
NCT03629873 Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects https://ClinicalTrials.gov/show/NCT03629873 Recruiting The First Affiliated Hospital with Nanjing Medical University 2019-08-01
NCT03617432 Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT03617432 Recruiting Peking University 2020-09-30
NCT03601819 Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT03601819 Recruiting University of Michigan Rogel Cancer Center 2021-09-30
NCT03598998 Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT03598998 Recruiting City of Hope Medical Center 2021-04-27
NCT03590574 Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03590574 Recruiting Autolus Limited 2021-07-31
NCT03586999 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas https://ClinicalTrials.gov/show/NCT03586999 Recruiting University of Colorado, Denver 2020-08-31
NCT03547700 Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT03547700 Recruiting Big Ten Cancer Research Consortium 2020-07-31
NCT03542266 CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03542266 Active, not recruiting Weill Medical College of Cornell University 2020-03-25
NCT03534180 Venetoclax in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03534180 Recruiting City of Hope Medical Center 2020-08-21
NCT03502629 Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) https://ClinicalTrials.gov/show/NCT03502629 Recruiting Genor Biopharma Co., Ltd. 2020-08-31
NCT03501576 Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma https://ClinicalTrials.gov/show/NCT03501576 Recruiting Emory University 2021-04-30
NCT03496779 Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine https://ClinicalTrials.gov/show/NCT03496779 Recruiting The Lymphoma Academic Research Organisation 2020-03-31
NCT03493451 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms https://ClinicalTrials.gov/show/NCT03493451 Active, not recruiting BeiGene 2021-02-28
NCT01261247 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01261247 Active, not recruiting Mayo Clinic 2016-05-09
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01226472 Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 https://ClinicalTrials.gov/show/NCT01226472 Completed Kyowa Kirin Pharmaceutical Development, Inc. 2012-09-30
NCT01198665 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT01198665 Completed Samsung Medical Center 2014-12-31
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01169298 A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01169298 Completed Celgene 2013-12-01
NCT01155817 Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT01155817 Completed Stanford University 2013-12-31
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01129180 Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01129180 Completed Ohio State University Comprehensive Cancer Center 2012-05-31
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT00970385 Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT00970385 Completed University Hospital, Grenoble 2002-12-31
NCT00930605 The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT00930605 Completed King Chulalongkorn Memorial Hospital 2006-11-30
NCT00901147 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00901147 Completed Singapore General Hospital 2014-01-31
NCT00891072 Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00891072 Completed National Cancer Institute (NCI) 2011-04-30
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00888927 Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00888927 Completed Kyowa Kirin Pharmaceutical Development, Inc. 2012-09-30
NCT00865969 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00865969 Completed Spectrum Pharmaceuticals, Inc 2014-10-31
NCT03922724 Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03922724 Recruiting National Institutes of Health Clinical Center (CC) 2023-05-27
NCT01401530 E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01401530 Completed Eisai Inc. 2015-08-31
NCT00791947 A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT https://ClinicalTrials.gov/show/NCT00791947 Completed University of Aarhus 2008-08-31
NCT00697346 Study of MLN8237 in Participants With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT00697346 Completed Takeda 2016-10-01
NCT00646854 Alemtuzumab and CHOP in T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00646854 Completed University of Aarhus 2016-12-31
NCT00644189 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00644189 Active, not recruiting Massachusetts General Hospital 2013-12-31
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00571662 Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00571662 Completed University of Nebraska 2008-12-31
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00481871 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies https://ClinicalTrials.gov/show/NCT00481871 Completed Acrotech Biopharma LLC 2011-05-31
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT00453427 Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT00453427 Completed Ontario Clinical Oncology Group (OCOG) 2013-06-30
NCT00426764 A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00426764 Completed Celgene 2010-11-11
NCT00406809 A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00406809 Completed AbbVie 2016-10-31
NCT00374699 Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas https://ClinicalTrials.gov/show/NCT00374699 Completed Samsung Medical Center 2009-09-30
NCT00364923 Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00364923 Completed Acrotech Biopharma LLC 2009-01-31
NCT00355472 Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL https://ClinicalTrials.gov/show/NCT00355472 Completed Kyowa Kirin Co., Ltd. 2008-10-31
NCT00337987 A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00337987 Completed Yale University 2007-12-31
NCT00290433 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00290433 Completed M.D. Anderson Cancer Center 2015-07-31
NCT00211185 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00211185 Completed Eisai Inc. 2008-08-31
NCT00136565 Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00136565 Completed Lymphoma Study Association 2011-04-18
NCT00131937 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00131937 Completed National Cancer Institute (NCI) 2011-09-30
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00082888 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00082888 Completed National Cancer Institute (NCI) 2009-05-20
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00038025 A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00038025 Completed M.D. Anderson Cancer Center 2006-11-29
NCT00007345 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00007345 Completed National Institutes of Health Clinical Center (CC) 2015-01-26

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03297697 Minimal Residual Disease in Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03297697 Active, not recruiting Washington University School of Medicine 2021-07-31
NCT03040206 Risk Stratification of Nodal PTCL https://ClinicalTrials.gov/show/NCT03040206 Completed Chonbuk National University Hospital 2017-06-30
NCT02788916 A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT02788916 Completed Takeda 2016-11-10
NCT03356678 Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03356678 Completed Samsung Medical Center 2017-06-30
NCT04213209 Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion “Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma” https://ClinicalTrials.gov/show/NCT04213209 Recruiting Takeda 2022-12-31
NCT03742921 ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03742921 Recruiting Celgene 2023-04-17
NCT01142674 T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01142674 Completed Associazione Angela Serra per la ricerca sul cancro 2016-07-31
NCT01110733 Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry https://ClinicalTrials.gov/show/NCT01110733 Completed Acrotech Biopharma LLC 2019-12-31
NCT00705809 T-Cell Project: Epidemiologic Component https://ClinicalTrials.gov/show/NCT00705809 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03964480 Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. https://ClinicalTrials.gov/show/NCT03964480 Recruiting Associazione Angela Serra per la ricerca sul cancro 2023-01-30